Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, explains the advances in the treatment of HER2-positive breast cancer.
Rugo touches on the importance of three treatments: pertuzumab, which is approved in the first line, T-DM1, which Rugo expects to be approved soon, and everolimus, which has seen improvement in toxicity management. Rugo is encouraged by the "explosion" of studies to identify biomarkers to predict response.
